NZ602122A - Peptide vaccines for cancers expressing tumor-associated antigens - Google Patents

Peptide vaccines for cancers expressing tumor-associated antigens

Info

Publication number
NZ602122A
NZ602122A NZ602122A NZ60212208A NZ602122A NZ 602122 A NZ602122 A NZ 602122A NZ 602122 A NZ602122 A NZ 602122A NZ 60212208 A NZ60212208 A NZ 60212208A NZ 602122 A NZ602122 A NZ 602122A
Authority
NZ
New Zealand
Prior art keywords
associated antigens
expressing tumor
peptide vaccines
cancers expressing
peptide
Prior art date
Application number
NZ602122A
Other languages
English (en)
Inventor
Tsunoda Takuya
Ohsawa Ryuji
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of NZ602122A publication Critical patent/NZ602122A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/422—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
NZ602122A 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens NZ602122A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90294907P 2007-02-21 2007-02-21
NZ591704A NZ591704A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens

Publications (1)

Publication Number Publication Date
NZ602122A true NZ602122A (en) 2014-03-28

Family

ID=39709837

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ602122A NZ602122A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens
NZ579768A NZ579768A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing cadherin 3 tumor-associated antigens
NZ602119A NZ602119A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens
NZ591704A NZ591704A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ579768A NZ579768A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing cadherin 3 tumor-associated antigens
NZ602119A NZ602119A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens
NZ591704A NZ591704A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens

Country Status (27)

Country Link
EP (20) EP2565203A1 (enExample)
JP (6) JP5239103B2 (enExample)
KR (8) KR101540000B1 (enExample)
CN (4) CN101663315B (enExample)
AR (1) AR068302A1 (enExample)
AU (1) AU2008218463B2 (enExample)
BR (1) BRPI0808421B1 (enExample)
CA (3) CA2992074C (enExample)
CO (1) CO6190536A2 (enExample)
CY (2) CY1114590T1 (enExample)
DK (3) DK2476694T3 (enExample)
ES (6) ES2532708T3 (enExample)
HR (3) HRP20131044T1 (enExample)
IL (10) IL200478A (enExample)
MX (4) MX337456B (enExample)
MY (2) MY173379A (enExample)
NZ (4) NZ602122A (enExample)
PH (1) PH12014501642B1 (enExample)
PL (3) PL2476694T3 (enExample)
PT (2) PT2121731E (enExample)
RU (1) RU2464275C2 (enExample)
SG (3) SG10201506589WA (enExample)
SI (3) SI2121731T1 (enExample)
TW (5) TWI615403B (enExample)
UA (1) UA100372C2 (enExample)
WO (1) WO2008102557A1 (enExample)
ZA (1) ZA200905881B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882698B (zh) 2003-08-20 2011-05-25 肿瘤疗法科学股份有限公司 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
UA100127C2 (ru) 2007-08-20 2012-11-26 Онкотерапи Саенс, Инк. Пептид cdh3 и лекарственное средство, содержащее его
JP5593560B2 (ja) 2008-06-30 2014-09-24 オンコセラピー・サイエンス株式会社 放射性同位体標識で標識された抗ｃｄｈ３抗体およびその使用
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI543767B (zh) 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
RU2532105C2 (ru) * 2008-10-22 2014-10-27 Онкотерапи Сайенс, Инк. Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины
TWI500932B (zh) * 2008-12-05 2015-09-21 Oncotherapy Science Inc Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
US8735361B2 (en) 2008-12-24 2014-05-27 Oncotherapy Science, Inc. C1ORF59 peptides and vaccines including the same
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
ES2701626T3 (es) 2009-12-28 2019-02-25 Oncotherapy Science Inc Anticuerpos anti-CDH3 y sus usos
EP2547359B1 (en) 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibitors of beta integrin-g protein alpha subunit binding interactions
TWI538685B (zh) 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
BR112013013158B1 (pt) * 2010-12-02 2020-04-28 Oncotherapy Science Inc composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso
EP2790738B1 (en) * 2011-12-14 2019-08-14 The Board of Regents of The University of Texas System Collateral gene inactivation biomarkers and targets for cancer therapy
US20150359864A1 (en) * 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
JP6255594B2 (ja) * 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＬＹ６Ｋエピトープペプチドおよびこれを含有するワクチン
WO2014010231A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Kif20a epitope peptides for th1 cells and vaccines containing the same
NO2891663T3 (enExample) 2012-08-31 2018-05-19
PL2895600T3 (pl) * 2012-09-11 2020-10-05 Oncotherapy Science, Inc. Peptydy UBE2T i szczepionki je zawierające
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
WO2015005479A1 (ja) * 2013-07-12 2015-01-15 大日本住友製薬株式会社 腫瘍抗原ペプチド
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
RU2016151645A (ru) 2014-07-01 2018-08-03 Пфайзер Инк. Биспецифические гетеродимерные диантитела и их применение
AU2015300260B2 (en) * 2014-08-04 2020-01-02 Oncotherapy Science, Inc. URLC10-derived peptide and vaccine containing same
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN104975082B (zh) * 2015-06-05 2018-11-02 复旦大学附属肿瘤医院 一组用于评估肺癌预后的基因及其应用
SI3436048T1 (sl) * 2016-03-31 2025-10-30 Biontech Us Inc. Neoantigeni in načini uporabe
CN110214144B (zh) * 2016-11-16 2023-05-02 深圳华大生命科学研究院 多肽及其应用
MX2019008878A (es) 2017-01-25 2020-02-13 Ose Immunotherapeutics Metodo para fabricar una emulsion estable para suministro de peptidos.
EP3601539A4 (en) * 2017-03-28 2021-01-13 Zhenglun Zhu METHODS OF TREATING NEOPLASIC DISEASES
WO2019031938A2 (ko) * 2017-08-10 2019-02-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
CN112812153B (zh) * 2018-02-15 2022-06-14 国立大学法人旭川医科大学 癌症抗原肽
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102335916B1 (ko) * 2019-04-22 2021-12-08 한국과학기술연구원 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN113117055A (zh) * 2019-12-31 2021-07-16 上海细胞治疗集团有限公司 一种特异性结合hla-a24分型的多肽组合物及应用
CN117143206B (zh) * 2023-08-03 2024-09-03 华南农业大学 Alv-j mhc-b21限制性表位肽及其筛选方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
NZ231899A (en) * 1985-10-03 1991-07-26 Genentech Inc Human or porcine inhibin peptide compositions and dna encoding them
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2084180A1 (en) * 1991-12-11 1993-06-12 Paul P. Hung Expression of specific immunogens using viral antigens
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
JPH09512167A (ja) * 1994-04-15 1997-12-09 アムジエン・インコーポレーテツド Ｈｅｋ５、ｈｅｋ７、ｈｅｋ８、ｈｅｋ１１、新規なｅｐｈ様受容体タンパク質チロシンキナーゼ
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
AU6632496A (en) 1995-08-03 1997-03-05 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
WO1998045433A1 (en) * 1997-04-04 1998-10-15 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1022286A4 (en) * 1997-10-07 2003-04-09 Ono Pharmaceutical Co POLYPEPTIDES, FOR ENDING CODNA AND THEIR USE
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
WO2001029221A2 (en) * 1999-10-20 2001-04-26 Zymogenetics, Inc. Proteins and polynucleotides encoding them
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
WO2002008765A2 (en) * 2000-07-26 2002-01-31 Stanford University Basal cell markers in breast cancer and uses thereof
US6830885B1 (en) * 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
WO2002078524A2 (en) * 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
EP1463928A2 (en) * 2001-04-18 2004-10-06 Protein Design Labs Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002347428A1 (en) * 2001-06-18 2003-01-02 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
EP1487857A4 (en) * 2002-03-07 2006-08-09 Ludwig Inst Cancer Res BLOOD AND LYMPHATIC ENDOTHELIAL CELL GENES
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040224408A1 (en) * 2002-12-10 2004-11-11 Jean-Philippe Girard THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
AU2003297318A1 (en) * 2002-12-20 2004-07-22 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
TWI324608B (en) * 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
EP1651775A2 (en) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN1882698B (zh) * 2003-08-20 2011-05-25 肿瘤疗法科学股份有限公司 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
EP1730279A2 (en) * 2004-02-27 2006-12-13 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
KR101234281B1 (ko) * 2004-04-09 2013-02-18 가부시키가이샤 진케어켄큐쇼 염색체 안정화에 관한 유전자를 표적으로 하는 암세포 특이적 아포토시스 유도제
EP1756147A2 (en) * 2004-06-01 2007-02-28 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
EP1859266A4 (en) * 2005-02-24 2010-07-28 Cemines Inc COMPOSITIONS AND METHODS FOR CLASSIFYING BIOLOGICAL SAMPLES
EP2325305B1 (en) * 2005-02-25 2014-02-12 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
CN100348614C (zh) * 2005-06-03 2007-11-14 北京大学 一种肝癌－睾丸特异性抗原蛋白质和抗原肽
US8030443B2 (en) * 2005-08-09 2011-10-04 Kurume University Squamous cell carcinoma antigen-derived peptide binding to HLA-A24 molecule
EP1923463B1 (en) * 2005-08-09 2011-10-05 Oncotherapy Science, Inc. Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hla-a2-positive patient and pharmaceutical comprising the antigen
US8003770B2 (en) 2005-09-13 2011-08-23 Mie University T-cell receptor and nucleic acid encoding the receptor
US20090263832A1 (en) * 2005-11-30 2009-10-22 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in Leukemia Signaling Pathways
EP2002259B1 (en) * 2006-04-10 2012-05-16 Genentech, Inc. Disheveled PDZ modulators
US8053557B2 (en) * 2006-06-16 2011-11-08 Onco Therapy Science, Inc. SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same
US20090081659A1 (en) * 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) * 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
UA100127C2 (ru) * 2007-08-20 2012-11-26 Онкотерапи Саенс, Инк. Пептид cdh3 и лекарственное средство, содержащее его
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TWI543767B (zh) * 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
EP2483690A1 (de) * 2009-09-29 2012-08-08 Protagen AG Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung

Also Published As

Publication number Publication date
JP5239104B2 (ja) 2013-07-17
PH12014501642A1 (en) 2015-12-02
KR20160045939A (ko) 2016-04-27
IL219043A0 (en) 2012-05-31
EP2573110A3 (en) 2013-09-04
JP5874158B2 (ja) 2016-03-02
EP2465867A3 (en) 2012-10-10
CN101663315B (zh) 2014-10-15
IL219048A0 (en) 2012-05-31
HK1172344A1 (en) 2013-04-19
HK1172345A1 (en) 2013-04-19
EP2476695A2 (en) 2012-07-18
WO2008102557A1 (en) 2008-08-28
EP2583976A2 (en) 2013-04-24
DK2121731T3 (da) 2013-10-21
ES2527397T3 (es) 2015-01-23
PL2465864T3 (pl) 2015-03-31
RU2464275C2 (ru) 2012-10-20
TW201538522A (zh) 2015-10-16
SG10201506589WA (en) 2015-09-29
EP2476693A3 (en) 2012-10-03
EP2476692B1 (en) 2015-04-15
IL200478A (en) 2015-11-30
EP2574623A2 (en) 2013-04-03
EP2476692A3 (en) 2012-12-19
CY1115841T1 (el) 2017-01-25
EP2574623A3 (en) 2013-07-17
HRP20131044T1 (hr) 2013-12-06
TWI494319B (zh) 2015-08-01
ES2541863T3 (es) 2015-07-27
CN101663315A (zh) 2010-03-03
HK1172041A1 (en) 2013-04-12
MY173379A (en) 2020-01-21
PL2476694T3 (pl) 2015-04-30
SI2465864T1 (sl) 2014-12-31
JP2010209060A (ja) 2010-09-24
TWI438207B (zh) 2014-05-21
KR101540000B1 (ko) 2015-07-29
EP2465866A2 (en) 2012-06-20
ES2540893T3 (es) 2015-07-14
EP2573110A2 (en) 2013-03-27
CA2992074C (en) 2021-01-05
KR20140130507A (ko) 2014-11-10
AU2008218463B2 (en) 2013-01-17
KR20150064236A (ko) 2015-06-10
KR101511134B1 (ko) 2015-04-28
IL219045A0 (en) 2012-05-31
RU2009135020A (ru) 2011-03-27
SI2121731T1 (sl) 2013-10-30
CO6190536A2 (es) 2010-08-19
SG10201909675QA (en) 2019-11-28
DK2476694T3 (en) 2014-12-08
PT2121731E (pt) 2013-10-24
CN103351423B (zh) 2016-09-28
EP2583976A3 (en) 2013-10-23
UA100372C2 (ru) 2012-12-25
EP2573109A2 (en) 2013-03-27
TW201623325A (zh) 2016-07-01
KR101511140B1 (ko) 2015-04-10
EP2465865A3 (en) 2013-07-24
KR101543623B1 (ko) 2015-08-11
ES2435194T3 (es) 2013-12-16
KR20150116463A (ko) 2015-10-15
AU2008218463A2 (en) 2009-11-26
AU2008218463A1 (en) 2008-08-28
TWI610939B (zh) 2018-01-11
EP2465865A2 (en) 2012-06-20
EP2565203A1 (en) 2013-03-06
CA2919248A1 (en) 2008-08-28
DK2465864T3 (en) 2014-11-24
MX359680B (es) 2018-09-28
KR20140121489A (ko) 2014-10-15
NZ602119A (en) 2014-03-28
EP2570429A3 (en) 2013-08-28
EP2476695A3 (en) 2012-12-12
EP2465866A3 (en) 2012-10-10
JP2013116895A (ja) 2013-06-13
TW200844111A (en) 2008-11-16
JP2016094459A (ja) 2016-05-26
JP2010519176A (ja) 2010-06-03
EP2465864A3 (en) 2012-10-03
EP2567971A2 (en) 2013-03-13
EP2121731A4 (en) 2010-04-21
CY1114590T1 (el) 2016-10-05
EP2476694A3 (en) 2013-04-24
EP2121731B1 (en) 2013-08-14
EP2594582A2 (en) 2013-05-22
HK1134507A1 (en) 2010-04-30
IL219040A0 (en) 2012-05-31
IL219044A (en) 2014-12-31
CN104292299A (zh) 2015-01-21
EP2476693A2 (en) 2012-07-18
EP2570428A2 (en) 2013-03-20
MX337417B (es) 2016-03-03
BRPI0808421A2 (pt) 2017-08-29
EP2465864B1 (en) 2014-10-08
IL219041A (en) 2014-12-31
TWI615403B (zh) 2018-02-21
CN104292299B (zh) 2017-09-29
PL2121731T3 (pl) 2014-01-31
IL219042A0 (en) 2012-05-31
EP2476693B1 (en) 2014-12-24
KR101644877B1 (ko) 2016-08-03
EP2476694B1 (en) 2014-11-19
EP2465865B1 (en) 2016-11-02
EP2570429A2 (en) 2013-03-20
KR20150018895A (ko) 2015-02-24
CA2678755A1 (en) 2008-08-28
CN102863514A (zh) 2013-01-09
IL219044A0 (en) 2012-05-31
EP2570428A3 (en) 2013-07-10
IL219046A0 (en) 2012-05-31
JP2014210804A (ja) 2014-11-13
JP2013091645A (ja) 2013-05-16
SG179402A1 (en) 2012-04-27
IL219047A0 (en) 2012-05-31
EP2465864A2 (en) 2012-06-20
EP2570430A3 (en) 2013-07-10
CN102863514B (zh) 2014-12-10
EP2465867A2 (en) 2012-06-20
HK1172042A1 (en) 2013-04-12
IL219043A (en) 2014-12-31
HRP20141233T1 (hr) 2015-02-27
EP2594581A2 (en) 2013-05-22
EP2567971A3 (en) 2013-06-26
MX2009009022A (es) 2010-03-03
KR20090121349A (ko) 2009-11-25
KR20130023407A (ko) 2013-03-07
KR101644871B1 (ko) 2016-08-02
PT2465864E (pt) 2015-01-14
EP2594581A3 (en) 2013-08-14
ZA200905881B (en) 2010-05-26
NZ591704A (en) 2012-09-28
EP2121731A1 (en) 2009-11-25
EP2570430A2 (en) 2013-03-20
ES2532708T3 (es) 2015-03-31
HK1172043A1 (en) 2013-04-12
TWI596109B (zh) 2017-08-21
CA2678755C (en) 2016-04-26
EP2594582A3 (en) 2013-08-14
SI2476694T1 (sl) 2015-02-27
CN103351423A (zh) 2013-10-16
EP2465867B1 (en) 2015-04-01
MX337456B (es) 2016-03-03
IL219046A (en) 2015-02-26
HRP20150108T1 (hr) 2015-05-08
IL219042A (en) 2016-03-31
JP5608953B2 (ja) 2014-10-22
ES2530777T3 (es) 2015-03-05
IL219048A (en) 2015-07-30
IL219040A (en) 2014-12-31
IL219041A0 (en) 2012-05-31
JP5614761B2 (ja) 2014-10-29
TW201422637A (zh) 2014-06-16
EP2476694A2 (en) 2012-07-18
IL200478A0 (en) 2010-04-29
TW201433574A (zh) 2014-09-01
MY155029A (en) 2015-08-28
JP5239103B2 (ja) 2013-07-17
EP2573109A3 (en) 2013-06-19
AR068302A1 (es) 2009-11-11
HK1172346A1 (en) 2013-04-19
CA2992074A1 (en) 2008-08-28
BRPI0808421B1 (pt) 2021-10-05
EP2476692A2 (en) 2012-07-18
PH12014501642B1 (en) 2015-12-02
NZ579768A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
NZ602122A (en) Peptide vaccines for cancers expressing tumor-associated antigens
UA110473C2 (uk) Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1
WO2009072610A1 (ja) 癌ワクチン組成物
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
NZ708205A (en) Immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2008040362A3 (en) Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
EP3552622A3 (en) Priming of an immune response
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
NZ570553A (en) Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
IL163812A (en) Immunizing composition, antigenic product and isolated antigenic peptide for inducing an immune response against beta-secretase cleavage site of amyloid the precursor protein
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
WO2007118660A3 (en) Her-2/neu multi-peptide vaccine
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
MX2013006213A (es) Proteina de funsion anticancer.
WO2010144231A3 (en) Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
WO2021005338A3 (en) Novel cancer antigens and methods
WO2020079448A9 (en) Novel cancer antigens and methods
TN2009000195A1 (en) Prime boost canine leishmania vaccine
WO2018065625A3 (en) Immunogenic compounds for cancer therapy
NZ589365A (en) Peptidyl diacylglycerides

Legal Events

Date Code Title Description
S23 Proceedings under section 23: mention of inventor as such in patent

Free format text: INVENTOR RYUJI OHSAWA, TAKUYA TSUNODA ADDED

Effective date: 20130221

ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS; FILING DATE: 29 AUG 2012; STATUS: REJECTED; TITLE: PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS; FILING DATE: 30 JAN 2013; STATUS: REJECTED; TITLE: PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS; FILING DATE: 10 JUN 2013; STATUS: REJECTED; TITLE: SPECWITHFIGURES; FILING DATE: 12 JUN 2013; STATUS: PROPOSED;

Effective date: 20130612

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 FEB 2015 BY DENNEMEYER + CO

Effective date: 20140821

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2016 BY DENNEMEYER + CO

Effective date: 20141219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2017 BY DENNEMEYER + CO

Effective date: 20160122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2018 BY DENNEMEYER + CO.

Effective date: 20170120

LAPS Patent lapsed